اخبار و اعلانات

 آمار

تعداد نشریات24
تعداد شماره‌ها859
تعداد مقالات7,646
تعداد مشاهده مقاله13,580,693
تعداد دریافت فایل اصل مقاله11,686,368
Valizadeh, Sepehr, Zehtabi, Mojtaba, Feiziordaklou, Neda, Akbarpour, Zahra, Khamaneh, Amir Mahdi, Raeisi, Mortaza. (1401). Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis. , 11(3), 133-141. doi: 10.22099/mbrc.2022.43947.1757
Sepehr Valizadeh; Mojtaba Zehtabi; Neda Feiziordaklou; Zahra Akbarpour; Amir Mahdi Khamaneh; Mortaza Raeisi. "Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis". , 11, 3, 1401, 133-141. doi: 10.22099/mbrc.2022.43947.1757
Valizadeh, Sepehr, Zehtabi, Mojtaba, Feiziordaklou, Neda, Akbarpour, Zahra, Khamaneh, Amir Mahdi, Raeisi, Mortaza. (1401). 'Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis', , 11(3), pp. 133-141. doi: 10.22099/mbrc.2022.43947.1757
Valizadeh, Sepehr, Zehtabi, Mojtaba, Feiziordaklou, Neda, Akbarpour, Zahra, Khamaneh, Amir Mahdi, Raeisi, Mortaza. Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis. , 1401; 11(3): 133-141. doi: 10.22099/mbrc.2022.43947.1757

Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis

Molecular Biology Research Communications
دوره 11، شماره 3، 2022، صفحه 133-141    اصل مقاله (217.33 K)
نوع مقاله: Original article
شناسه دیجیتال (DOI): 10.22099/mbrc.2022.43947.1757
نویسندگان
Sepehr Valizadeh1؛ Mojtaba Zehtabi2؛ Neda Feiziordaklou1؛ Zahra Akbarpour3؛ Amir Mahdi Khamaneh4؛ Mortaza Raeisi* 2
1Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
2Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3Rahat Breathe and Sleep Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
چکیده
Papillary thyroid carcinoma (PTC) accounts for approximately 80% of all human thyroid malignancies. Recently, there has been a dramatic rise in the prevalence of thyroid cancer all over the globe. Through analysis of the GEO database, GSE104005, the authors of the current research were able to determine the differential expression of microRNAs (DEMs) as well as their target genes. Real-time PCR was used on a total of 40 samples, 40 of which were from PTC samples and 40 from normal tissues, in order to validate the discovered DEMs and the genes. Gene Ontology (GO) categories were identified, and KEGG was used to conduct pathway enrichment analysis. The multiMiR R package was used to predict target genes of DEMs. Mir-142 was found to be overexpressed in PTC samples, as compared to normal tissues, and this was validated by the identification and validation. In addition, metal ion binding and the cellular response to metal ions were identified as essential pathways in the carcinogenesis of PTC. This demonstrates their significance in the development of this malignancy. The results of our research will serve as the foundation for further research in the area of miRNA-based cancer treatment.
کلیدواژه‌ها
Papillary thyroid cancer؛ MicroRNA؛ Bioinformatics؛ Microarray data analysis
سایر فایل های مرتبط با مقاله
مراجع
  1. Pishkari S, Paryan M, Hashemi M, Baldini E, Mohammadi-Yeganeh S. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. J Endocrinol Inves 2018;41:269-283.
  2. Silva-Vieira M, Carrilho Vaz S, Esteves S, Ferreira TC, Limbert E, Salgado L, Leite V. Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role?. Thyroid 2017;27:1068-1076.
  3. Ahmadieh H, Azar ST. Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines. J Thyroid Res 2012;2012:512401.
  4. Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly L. Undetectable thyroglobulin after total thyroidectomy in patients with low-and intermediate-risk papillary thyroid cancer—is there a need for radioactive iodine therapy?. Surgery 2012;152:1096-1105.
  5. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-1501.
  6. Fröhlich E, Wahl R. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. Cancer Treat Rev 2014;40:665-674.
  7. Sasanakietkul T, Murtha TD, Javid M, Korah R, Carling T. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. Mol Cell Endocrinol 2018;469:23-37.
  8. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non‐coding RNAs: regulators of disease. J Pathol 2010;220:126-139.
  9. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.
  10. Hausser J, Syed AP, Bilen B, Zavolan M. Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res 2013;23:604-615.
  11. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic Acids Res 2005;33(suppl. 1):D562-D566.
  12. Zhao Y, Wong L, Goh WWB. How to do quantile normalization correctly for gene expression data analyses. Sci Rep 2020;10:1-11.
  13. Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, Mahaffey S, Rossi S, Calin GA, Bemis L, Theodorescu D. The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations. Nucleic Acids Res 2014;42:e133.
  14. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
  15. Timalsina P, Charles K, Mondal AM. STRING PPI score to characterize protein subnetwork biomarkers for human diseases and pathways. 2014 IEEE International Conference on Bioinformatics and Bioengineering; 2014: IEEE.
  16. Bauer-Mehren A. Integration of genomic information with biological networks using Cytoscape. Methods Mol Biol 2013;1021:37-61.
  17. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009;285:116-126.
  18. Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J Transl Med 2012;10:1-21.
  19. Colamaio M, Puca F, Ragozzino E, Gemei M, Decaussin-Petrucci M, Aiello C, Bastos AU, Federico A, Chiappetta G, Vecchio LD, Torregrossa L, Battista S, Fusco A. miR-142–3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J Clin Endocrinol Metab 2015;100:E59-E69.
  20. Mansoori B, Mohammadi A, Gjerstorff MF, Shirjang S, Asadzadeh Z, Khaze V, Holmskov U, Kazemi T, Duijf PHG, Baradaran B. miR‐142‐3p is a tumor suppressor that inhibits estrogen receptor expression in ER‐positive breast cancer. J Cell Physiol 2019;234:16043-16053.
  21. Wang Z, Liu Z, Fang X, Yang H. MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem 2017;43:2505-2515.
آمار
تعداد مشاهده مقاله: 697
تعداد دریافت فایل اصل مقاله: 523


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب